Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Emavusertib in Combination With an Approved Bruton Tyrosine Kinase Inhibitor in Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies

NCT07271667 is registered in ClinicalTrials.gov with Curis, Inc. as lead sponsor.

NCT NCT07271667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07271667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Emavusertib in Combination With an Approved Bruton Tyrosine Kinase Inhibitor in Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies
Lead sponsor
Curis, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
April 23, 2026
Completion date
November 30, 2027
Enrollment
108 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell malignancies, chronic lymphocytic leukemia